(Q37203034)

18 August 2017

1 reference

14 November 2020

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy (English)

1 reference

18 August 2017

1 reference

14 November 2020

1 reference

14 November 2020

1 reference

31 July 2019

proto-oncogene protein

1 reference

PubMed

protein kinase inhibitors

2 August 2019

1 reference

2 October 2019

1 reference

20 November 2019

proto-oncogene proteins p21(ras)

1 reference

18 December 2019

1 reference

14 November 2020

1 reference

David Z Chang

1

1 reference

18 August 2017

Vikas Kumar

2

1 reference

18 August 2017

Ying Ma

3

1 reference

18 August 2017

Kuiyuan Li

4

1 reference

18 August 2017

Scott Kopetz

5

1 reference

18 August 2017

22 April 2009

13 references

Journal of Hematology & Oncology

18 August 2017

21 March 2019

3 April 2019

25 June 2019

31 July 2019

2 August 2019

28 September 2019

2 October 2019

20 November 2019

28 November 2019

15 December 2019

18 December 2019

14 November 2020

13 references

18 August 2017

21 March 2019

3 April 2019

25 June 2019

31 July 2019

2 August 2019

28 September 2019

2 October 2019

20 November 2019

28 November 2019

15 December 2019

18 December 2019

14 November 2020

2

1 reference

18 August 2017

18

1 reference

Creative Commons Attribution 2.0 Generic

18 August 2017

12 references

21 March 2019

3 April 2019

25 June 2019

31 July 2019

2 August 2019

28 September 2019

2 October 2019

20 November 2019

28 November 2019

15 December 2019

18 December 2019

on focus list of Wikimedia project

14 November 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1756-8722-2-18

0 references

cites work

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

6 September 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

Cetuximab for the treatment of colorectal cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

Oligonucleotide microarray-based mutation detection of the K-ras gene in colorectal cancers with use of competitive DNA hybridization.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2686726

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19386128

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1756-8722-2-18

1 reference

Dimensions Publication ID

18 August 2017

0 references

1 reference

18 August 2017

1 reference